Bachem and Debiopharm Sign Follow-up Contract

Bachem and Debiopharm announced the conclusion of a follow-up agreement for the long-term supply of Triptorelin Pamoate. Bachem has been supplying Triptorelin Pamoate, the active ingredient for Debiopharm's Decapeptyl (Trelstar in the U.S.), for the treatment of prostate cancer, endometriosis and premature puberty for over 15 years, initially on an individual order basis, since March 2006 in the frame of a long-term supply agreement. In view of the favourable development of Decapeptyl, the initial supply contract has been revisited. Under the terms of the follow-up agreement, Bachem will continue to supply Debiopharm with agreed quantities of Triptorelin Pamoate at fixed conditions. The ­delivery quantities are defined on the basis of detailed planning models and are supplied by Bachem through a call order.